Table 2.

Detailed demographic, behavioural and virological characteristics of participants with HCV reinfection (n=10)

Gender, age1	HIV	Mode of primary HCV	IDU		HCV genotype		Region sequenced	Time between EOT and reinfection (weeks)	ALT		Reinfection outcome
			At screening2	During follow-up	Primary	Reinfection			EOT	Reinfection
Confirmed reinfection
Male 29	No	IDU	Yes	Yes	3a	1a	E1/HVR1	18	21	53	Spontaneous clearance
Male 49	Yes	IDU	Yes	Yes	3a/1a	3a/1a	Core-E2	81	83	1135	Persistence
Male 36	No	IDU	Yes	Yes	1a	3a	E1/HVR1 Core-E2	30	26	319	Persistence
Male 44	Yes	Sexual	No	No	2a	1a/3a	Core-E2	40	58	565	Indeterminate
Male 50	Yes	Sexual	No	Yes	1a	1a	NS5B	65	18	15	Indeterminate
Male 62	Yes	IDU	Yes	Yes	3a	1a	Core-E2 NS5B	39	15	65	Persistence
Male 45	Yes	Sexual	No	No	1a	1a	Core-E2 NS5B	18	29	54	Persistence
Male 41	Yes	IDU	Yes	Yes	3a	1a	Core-E2 NS5B	9	23	910	Persistence
Possible reinfection
Male 35	No	IDU	Yes	Yes	3a	NA3	InnoLipa	31	15	14	Spontaneous clearance
Male 46	Yes	Sexual	No	Yes4	1a	NA3	InnoLipa	64	71	43	Spontaneous clearance

¹Age at study enrolment

²IDU within 6 months of study enrolment

³Unable to sequence due to low HCV RNA at time of viral recurrence

⁴Anabolic steroids

Abbreviations: ALT, alanine aminotransferase; EOT, end of treatment; IDU, injecting drug use¹ ALT, normal range 0–30 U/L